Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

U.S. government shutdown hampers FDA

Published 01/02/2019, 08:26 AM
Updated 01/02/2019, 08:26 AM
© Reuters.  U.S. government shutdown hampers FDA

© Reuters. U.S. government shutdown hampers FDA

  • FDA Commissioner Scott Gottlieb, M.D. says the U.S. government shutdown prevents the agency from accepting new product applications under user fee programs (PDUFA, GDUFA, BsUFA, MDUFA, ADUFA, AGDUFA) since it is unable to collect payments.
  • In addition, its Center for Biologics Evaluation and Research (CBER) will pause non-emergency work on whole blood, blood components for transfusion, allergenic extracts and certain other products.
  • Its Center for Drug Evaluation and Research (CDER) will pause all over-the-counter monograph drug activities. Emergency work will continue.
  • The 30-day review clock for pending IND amendments (non-user fee programs) will be suspended, but will resume when the shutdown is over.
  • Emergency INDs and IND amendments will continue to be reviewed, including those under user fee programs.
  • About 30% of the drug review process is paid for by appropriations so it will continue in part during the shutdown.
  • As everyone should know, the government impasse relates to President Trump's demand for ~$5B for a wall at the U.S./Mexico border.
  • ETFs: BIB, GRX, THW, BME, BIS, IXJ, ARKG, GNRX, CHNA, XLV, XBI, VHT, IYH, RYH, IBB, XHE, PJP
  • Now read: THW: Sitting Tight With A 12% Yield From This Well-Diversified CEF


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.